deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03049189

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)

Sponsor: ABX CRO

Conditions Neuroendocrine Tumors
Interventions 177Lu-edotreotide PRRT Amino-Acid Solution Everolimus
Updated 29 times since 2017 Last updated: May 26, 2025 Started: Feb 2, 2017 Primary completion: Nov 27, 2024 Completion: Nov 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Neuroendocrine Tumors, this trial is ongoing. The trial is conducted by ABX CRO and has accumulated 29 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Aug 2019 · 10 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Oct 2021 · 5 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

29 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 24 earlier versions

  1. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Feb 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  4. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jan 2022 — May 2022 [monthly]

    Recruiting PHASE3

  6. Oct 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  7. May 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  8. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  9. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  10. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  11. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  12. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  13. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  14. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  15. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  16. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  17. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  18. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  19. Oct 2018 — Aug 2019 [monthly]

    Recruiting PHASE3

  20. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  21. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  22. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  23. Sep 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  24. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ABX CRO
  • ITM Solucin GmbH
  • PSI CRO
Data source: ITM Solucin GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ann Arbor, United States , Bad Berka, Germany , Barcelona, Spain , Basel, Switzerland , Berlin, Germany , Bern, Switzerland , Bonn, Germany , Bron, France , Brussels, Belgium and 38 more locations